cl 387785 and thymidine

cl 387785 has been researched along with thymidine in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Erlichman, C; Goble, JM; James, CD; Lamont, JD; Mladek, AC; Rao, RD; Sarkaria, JN1

Other Studies

1 other study(ies) available for cl 387785 and thymidine

ArticleYear
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Immunoprecipitation; Models, Biological; Phosphoproteins; Phosphorylation; Protein Kinases; Quinazolines; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Thymidine; TOR Serine-Threonine Kinases

2005